CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study

DOI: 10.1128/CVI.00071-16

Article Information

DOI

PubMed

Published By

History

Editors and / or Reviewers

^aDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Lutherville, Maryland, USA
^bLyme Disease Research Foundation, Lutherville, Maryland, USA
^cDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA, and Veterans Affairs Palo Alto Health Care System CCSR, Palo Alto, California, USA
^dDepartment of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Address correspondence to John N. Aucott, jaucott2{at}jhmi.edu.
↵* Present address: Lauren A. Crowder, American Red Cross, Rockville, Maryland, USA; Lauren J. Lahey, Biophysics Graduate Program, Stanford University School of Medicine, Stanford, California, USA; Catriona A. Wagner, Immunology Graduate Program, University of Washington Department of Immunology, Seattle, Washington, USA.
Citation Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Bechtold KT. 2016. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol 23:757–766. doi:10.1128/CVI.00071-16.

Rendering graph...